Sage Therapeutics should price its experimental depression pill on 'value' despite political pressure, CEO says

"We feel we should be able to price it for the value it'll provide for patients," Sage Therapeutics CEO Jeff Jonas tells CNBC.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.